1887
Rapid communication Open Access
Like 0

Abstract

In France, blood donations are tested in pools of 96 samples for parvovirus B19 (B19V) DNA to discard plasma for fractionation when it contains high viral loads. Between January 2015 and March 2024, B19V-positive donations decreased during the COVID-19 pandemic, followed by a strong rebound in 2023 and unusually high circulation during winter 2023/24 (ca 10 times higher December 2023–March 2024 vs the pre-pandemic period). Variations over time are probably related to measures implemented to limit SARS-CoV-2 spread.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.21.2400253
2024-05-23
2024-07-14
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.21.2400253
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/21/eurosurv-29-21_1.html?itemId=/content/10.2807/1560-7917.ES.2024.29.21.2400253&mimeType=html&fmt=ahah

References

  1. Zaaijer HL, Koppelman MH, Farrington CP. Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect. 2004;132(6):1161-6.  https://doi.org/10.1017/S0950268804002730  PMID: 15635975 
  2. European Centre for Disease Prevention and Control (ECDC). Communicable disease threats report, 14-20 April 2024, week 16. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-14-20-april-2024-week-16
  3. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol. 2004;78(22):12169-78.  https://doi.org/10.1128/JVI.78.22.12169-12178.2004  PMID: 15507603 
  4. Matsukura H, Shibata S, Tani Y, Shibata H, Furuta RA. Persistent infection by human parvovirus B19 in qualified blood donors. Transfusion. 2008;48(5):1036-7.  https://doi.org/10.1111/j.1537-2995.2008.01704.x  PMID: 18454740 
  5. Sun P, Jiang P, Liu Q, Zhang R, Wang Z, Cao H, et al. Parvovirus B19 DNA and antibodies in Chinese plasma donors, plasma pools and plasma derivatives. PeerJ. 2023;11:e15698.  https://doi.org/10.7717/peerj.15698  PMID: 37554334 
  6. Williams S, Ratcliff J, Nguyen D, Simmonds P, Harvala H, International Survey Group. Detection frequencies and viral load distribution of parvovirus B19 DNA in blood and plasma donations in England. Transfus Med. 2022;32(5):402-9.  https://doi.org/10.1111/tme.12893  PMID: 35751630 
  7. Gowland P, Fontana S, Stolz M, Andina N, Niederhauser C. Parvovirus B19 passive transmission by transfusion of intercept® blood system-treated platelet concentrate. Transfus Med Hemother. 2016;43(3):198-202.  https://doi.org/10.1159/000445195  PMID: 27403092 
  8. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999;13(3):194-204.  https://doi.org/10.1016/S0887-7963(99)80033-9  PMID: 10425692 
  9. Marano G, Vaglio S, Pupella S, Facco G, Calizzani G, Candura F, et al. Human parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus. 2015;13(2):184-96. PMID: 25849894 
  10. Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion. 2011;51(9):1887-95.  https://doi.org/10.1111/j.1537-2995.2010.03047.x  PMID: 21332725 
  11. Human anti-D immunoglobulin for Intravenous Administration. In: European Pharmacopoeia. 10th ed. Strasbourg: The European Pharmacopoeia Commission; 2020.Available from: https://www.edqm.eu/en/-/shutdown-of-european-pharmacopoeia-10th-edition
  12. Nawrocki J, Olin K, Holdrege MC, Hartsell J, Meyers L, Cox C, et al. The effects of social distancing policies on non-SARS-CoV-2 respiratory pathogens. Open Forum Infect Dis. 2021;8(7):ofab133.  https://doi.org/10.1093/ofid/ofab133  PMID: 34322558 
  13. Launay T, Souty C, Vilcu AM, Turbelin C, Blanchon T, Guerrisi C, et al. Common communicable diseases in the general population in France during the COVID-19 pandemic. PLoS One. 2021;16(10):e0258391.  https://doi.org/10.1371/journal.pone.0258391  PMID: 34634090 
  14. Sanz-Muñoz I, Tamames-Gómez S, Castrodeza-Sanz J, Eiros-Bouza JM, de Lejarazu-Leonardo RO. Social distancing, lockdown and the wide use of mask; a magic solution or a double-edged sword for respiratory viruses epidemiology? Vaccines (Basel). 2021;9(6):595.  https://doi.org/10.3390/vaccines9060595  PMID: 34205119 
  15. Bernard-Stoecklin S, Équipes de surveillance de la grippe. Surveillance de la grippe en France, saison 2022-2023. [Influenza surveillance in France, 2022-2023 season. Bull Épidémiol Hebd. 2023;(19):382-97. French. Available from: http://beh.santepubliquefrance.fr/beh/2023/19/2023_19_1.html
  16. Santé Publique France. Bronchiolite. Bilan de la surveillance 2022-2023. [Bronchiolitis. Surveillance report 2022-2023]. Saint-Maurice: Santé Publique France; 2023. French. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-national/bulletin-epidemiologique-bronchiolite.-bilan-de-la-surveillance-2022-2023
  17. Molenaar-de Backer MW, Hogema BM, Koppelman MH, van de Laar TJ, Slot E, Zaaijer HL. Lower incidence of parvovirus-B19 infections in Dutch blood donors during SARS-CoV-2 Pandemic. Microbiol Spectr. 2021;9(2):e0025321.  https://doi.org/10.1128/Spectrum.00253-21  PMID: 34523999 
  18. Sauleda S, Piron M, Bes M, Martinez-Llonch N, Puig L. Changes in parvovirus B19 positivity rates in plasma units for fractionation: An unexpected effect of non-pharmaceutical interventions against COVID-19? Vox Sang. 2022;117(4):626-7.  https://doi.org/10.1111/vox.13229  PMID: 34877666 
  19. Drews SJ, Charlton C, O’Brien SF, Burugu S, Denomme GA. Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID-19 restriction in March 2020. Vox Sang. 2024;vox.13616.  https://doi.org/10.1111/vox.13616  PMID: 38482941 
  20. Patalon T, Saciuk Y, Trotzky D, Pachys G, Ben-Tov A, Segal Y, et al. An outbreak of parvovirus B19 in Israel. Viruses. 2023;15(11):2261.  https://doi.org/10.3390/v15112261  PMID: 38005937 
  21. Fourgeaud J, Allali S, Toubiana J, Pinhas Y, Frange P, Leruez-Ville M, et al. Post-COVID-19 pandemic outbreak of severe parvovirus B19 primary infections in Paris, France: 10-year interrupted time-series analysis (2012-2023). J Clin Virol. 2023;167:105576.  https://doi.org/10.1016/j.jcv.2023.105576  PMID: 37633184 
  22. Semaille C (directrice de publication). Epidémie d’infections à Parvovirus B-19. [Epidemic of parvovirus B-19 infections]. Saint-Maurice: Santé publique France; 2024. French. Available from: https://www.santepubliquefrance.fr/content/download/620047/4261122?version=2#:~:text=Une%20%C3%A9pid%C3%A9mie%20d'infections%20%C3%A0,atteint%20au%20mois%20de%20mars
/content/10.2807/1560-7917.ES.2024.29.21.2400253
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error